RecruitingRecruiting
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
NCT07332455 · GlaxoSmithKline
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
About this study
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Eligibility criteria
Inclusion Criteria:
* Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.
* Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
* Progression on ADT and \>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane-based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use.
Exclusion Criteria:
* Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.
* Impaired cardiac function or clinically significant cardiac disease.
* Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.
* Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.
Study design
Enrollment target: 54 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-02-10
Estimated completion: 2030-03-26
Last updated: 2026-11-09
Interventions
Drug: GSK5471713
Primary outcomes
- • Number of participants with dose limiting toxicities (DLTs) (28 days)
- • Number of participants with adverse events (AEs), and serious adverse events (SAEs) (Approximately 45 months)
- • Number of participants with adverse events (AEs), and serious adverse events (SAEs) by Severity (Approximately 45 months)
Sponsor
GlaxoSmithKline · industry
Contacts & investigators
ContactUS GSK Clinical Trials Call Center · contact · GSKClinicalSupportHD@gsk.com · 877-379-3718
ContactEU GSK Clinical Trials Call Center · contact · GSKClinicalSupportHD@gsk.com · +44 (0) 20 89904466
InvestigatorGSK Clinical Trials · study_director, GlaxoSmithKline
All locations (20)
GSK Investigational SiteRecruiting
La Jolla, California, United States
GSK Investigational SiteRecruiting
Los Angeles, California, United States
GSK Investigational SiteRecruiting
Grand Rapids, Michigan, United States
GSK Investigational SiteRecruiting
Philadelphia, Pennsylvania, United States
GSK Investigational SiteRecruiting
West Valley City, Utah, United States
GSK Investigational SiteRecruiting
Melbourne, Victoria, Australia
GSK Investigational SiteRecruiting
Toronto, Ontario, Canada
GSK Investigational SiteRecruiting
Montreal, Quebec, Canada
GSK Investigational SiteRecruiting
Montreal, Quebec, Canada
GSK Investigational SiteRecruiting
Montpellier, France
GSK Investigational SiteRecruiting
Villejuif, France
GSK Investigational SiteRecruiting
Tokyo, Japan
GSK Investigational SiteRecruiting
Tokyo, Japan
GSK Investigational SiteRecruiting
Amsterdam, Netherlands
GSK Investigational SiteRecruiting
Nijmegen, Netherlands
GSK Investigational SiteRecruiting
Seoul, Seoul Teugbyeolsi, South Korea
GSK Investigational SiteRecruiting
Seoul, South Korea
GSK Investigational SiteRecruiting
Logroño, La Rioja, Spain
GSK Investigational SiteRecruiting
Barcelona, Spain
GSK Investigational SiteRecruiting
Málaga, Spain